Posted by Michael Wonder on 16 Feb 2022
Saphnelo approved in the EU for the treatment of moderate to severe systemic lupus erythematosus
16 February 2022 - Saphnelo is a first in class type I interferon receptor antibody and the only new medicine in over a decade for patients with systemic lupus erythematosus.
AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus, despite receiving standard therapy.
